Modulation of CD28 expression: distinct regulatory pathways during activation and replicative senescence.
暂无分享,去创建一个
A. Vallejo | C. Weyand | J. Goronzy | C. Weyand | J. Brandes
[1] A. Vallejo,et al. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28- T cells from rheumatoid arthritis patients. , 1998, Journal of immunology.
[2] C. Geisler,et al. Two distinct pathways exist for down-regulation of the TCR. , 1998, Journal of immunology.
[3] Martine,et al. CD28, a marker associated with tumoral expansion in multiple myeloma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] C. Weyand,et al. Functional properties of CD4+CD28− T cells in the aging immune system , 1998, Mechanisms of Ageing and Development.
[5] Walker,et al. Down‐regulation of CD28 via Fas (CD95): influence of CD28 on T‐cell apoptosis , 1998, Immunology.
[6] A. Vallejo,et al. Aging-related Deficiency of CD28 Expression in CD4+ T Cells Is Associated with the Loss of Gene-specific Nuclear Factor Binding Activity* , 1998, The Journal of Biological Chemistry.
[7] Merino,et al. Progressive decrease of CD8high+ CD28+ CD57− cells with ageing , 1998, Clinical and experimental immunology.
[8] B. Klein,et al. Malignant plasma cell lines express a functional CD28 molecule , 1998, Leukemia.
[9] A. Balsari,et al. Contribution of CD4+, CD8+CD28+, and CD8+CD28- T cells to CD3+ lymphocyte homeostasis during the natural course of HIV-1 infection. , 1998, The Journal of clinical investigation.
[10] G. Pawelec,et al. Human T‐cell clones in long‐term culture as a model of immunosenescence , 1997, Immunological reviews.
[11] L. Turka,et al. Differential down-regulation of CD28 by B7-1 and B7-2 engagement. , 1997, Transplantation.
[12] L. Tuosto,et al. Quantitative Contribution of CD4 and CD8 to T Cell Antigen Receptor Serial Triggering , 1997, The Journal of experimental medicine.
[13] R. Effros. Loss of CD28 expression on T lymphocytes: a marker of replicative senescence. , 1997, Developmental and comparative immunology.
[14] D. Schaid,et al. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. , 1997, Arthritis and rheumatism.
[15] C. Weyand,et al. Co‐stimulatory pathways controlling activation and peripheral tolerance of human CD4+CD28− T cells , 1997, European journal of immunology.
[16] A. Minguela,et al. CD28 expression on peripheral blood T lymphocytes after orthotopic liver transplant: upregulation in acute rejection. , 1997, Human immunology.
[17] M. Hazzan,et al. Recall response to cytomegalovirus in allograft recipients: mobilization of CD57+, CD28+ cells before expansion of CD57+, CD28- cells within the CD8+ T lymphocyte compartment. , 1997, Transplantation.
[18] M. Jackson,et al. Requirements for Peptide-induced T Cell Receptor Downregulation on Naive CD8+ T Cells , 1997, The Journal of experimental medicine.
[19] T. Lloyd,et al. Regulation of CD28 costimulation in human CD8+ T cells. , 1997, Journal of immunology.
[20] P. Linsley,et al. CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics , 1997, The Journal of experimental medicine.
[21] L. Pease,et al. The Locus-specific Enhancer Activity of the Class I Major Histocompatibility Complex Interferon-responsive Element Is Associated with a γ-Interferon (IFN)-inducible Factor Distinct from STAT1α, p48, and IFN Regulatory Factor-1* , 1996, The Journal of Biological Chemistry.
[22] P. Linsley,et al. Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions* , 1996, The Journal of Biological Chemistry.
[23] C. Weyand,et al. The Repertoire of CD4+ CD28− T Cells in Rheumatoid Arthritis , 1996, Molecular medicine.
[24] C. Franceschi,et al. Expansion of cytotoxic CD8+ CD28− T cells in healthy ageing people, including centenarians , 1996, Immunology.
[25] M. Salmon,et al. Factors that influence activated CD8+ T-cell apoptosis in patients with acute herpesvirus infections: loss of costimulatory molecules CD28, CD5 and CD6 but relative maintenance of Bax and Bcl-X expression. , 1996, Immunology.
[26] I. Kariv,et al. Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function. , 1996, Journal of immunology.
[27] P. Carlson,et al. Oligoclonal T cell proliferation in patients with rheumatoid arthritis and their unaffected siblings. , 1996, Arthritis and rheumatism.
[28] P. Gregersen,et al. Oligoclonality of CD8+ T cells in health and disease: aging, infection, or immune regulation? , 1996, Human immunology.
[29] H. Ostrer,et al. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. , 1996, Journal of immunology.
[30] J. Bluestone,et al. CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.
[31] G. Ahmann,et al. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. , 1996, Leukemia.
[32] C. Weyand,et al. CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. , 1996, The Journal of clinical investigation.
[33] H. Volk,et al. The enigma of CD57+CD28– T cell expansion—anergy or activation? , 1996, Clinical and experimental immunology.
[34] O. Martins-Filho,et al. Chagasic Patients Lack CD28 Expression on Many of Their Circulating T Lymphocytes , 1996, Scandinavian journal of immunology.
[35] B. Barlogie,et al. 2Biological aspects of multiple myeloma , 1995 .
[36] C. Thompson,et al. CD28 and apoptosis. , 1995, Current opinion in immunology.
[37] C. Thompson,et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. , 1995, Immunity.
[38] J. Ceuppens,et al. Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 down‐regulation on CD8+ T cells from HIV‐infected subjects , 1995, Clinical and experimental immunology.
[39] R. Abraham,et al. Protein-tyrosine kinase-dependent activation of STAT transcription factors in interleukin-2- or interleukin-4-stimulated T lymphocytes , 1995, Journal of Biological Chemistry.
[40] L. Pease,et al. Structure of the MHC A and B locus promoters in hominoids. Insights on the evolution of the class I MHC multigene family. , 1995, Journal of immunology.
[41] P. Linsley,et al. CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation. , 1995, Research in immunology.
[42] P. Linsley,et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.
[43] R. Effros,et al. Decline in CD28+ T cells in centenarians and in long-term T cell cultures: A possible cause for both in vivo and in vitro immunosenescence , 1994, Experimental Gerontology.
[44] P. Linsley,et al. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. , 1994, Journal of immunology.
[45] C. Weyand,et al. Dominant clonotypes in the repertoire of peripheral CD4+ T cells in rheumatoid arthritis. , 1994, The Journal of clinical investigation.
[46] R. Bataille,et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. , 1994, Blood.
[47] D N Posnett,et al. Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy" [published erratum appears in J Exp Med 1994 Mar 1;179(3):1077] , 1994, The Journal of experimental medicine.
[48] G. Ahmann,et al. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. , 1993, Cancer research.
[49] J. Mcarthur,et al. CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4 , 1993, The Journal of experimental medicine.
[50] M. Marsh,et al. Phorbol ester-induced downregulation of CD4 is a multistep process involving dissociation from p56lck, increased association with clathrin- coated pits, and altered endosomal sorting , 1993, The Journal of experimental medicine.
[51] K P Lee,et al. Differential T cell costimulatory requirements in CD28-deficient mice. , 1993, Science.
[52] P. Linsley,et al. The role of the CD28 receptor during T cell responses to antigen. , 1993, Annual review of immunology.
[53] J. Allison,et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.
[54] C. Thompson,et al. The genomic organization of the CD28 gene. Implications for the regulation of CD28 mRNA expression and heterogeneity. , 1990, Journal of immunology.
[55] C. Thompson,et al. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. , 1990, Journal of immunology.
[56] C. Thompson,et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[57] B. Seed,et al. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[58] C. Fathman,et al. Modulation of CD4 by antigenic activation. , 1987, Journal of immunology.
[59] S. Hickman. Benign monoclonal gammopathy. , 1982, Archives of internal medicine.